Company profile TRVN

Trevena Inc
trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased liga...nd drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization. Show More
Quarter analysis & expected interest

There is not enough data for Trevena - biopharmaceutical company to provide analysis

Correlation between past revenue and Trevena - biopharmaceutical company search interest

There is not enough data for Trevena - biopharmaceutical company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Trevena - biopharmaceutical company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for OLINVYK (Oliceridine) injection to provide analysis

Correlation between past revenue and OLINVYK (Oliceridine) injection search interest

There is not enough data for OLINVYK (Oliceridine) injection to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for OLINVYK (Oliceridine) injection to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TRV250 - G protein biased delta-opioid receptor agonist for acute migraine to provide analysis

Correlation between past revenue and TRV250 - G protein biased delta-opioid receptor agonist for acute migraine search interest

There is not enough data for TRV250 - G protein biased delta-opioid receptor agonist for acute migraine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TRV250 - G protein biased delta-opioid receptor agonist for acute migraine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TRV734 - G protein biased ligand of MOR for acute and chronic pain to provide analysis

Correlation between past revenue and TRV734 - G protein biased ligand of MOR for acute and chronic pain search interest

There is not enough data for TRV734 - G protein biased ligand of MOR for acute and chronic pain to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TRV734 - G protein biased ligand of MOR for acute and chronic pain to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for TRV045 - S1P modulator for chronic pain to provide analysis

Correlation between past revenue and TRV045 - S1P modulator for chronic pain search interest

There is not enough data for TRV045 - S1P modulator for chronic pain to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for TRV045 - S1P modulator for chronic pain to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 09 2023 02:39:51.

After 34 days of this quarter the interest is at 382.0. Based on that we can calculate that during remaining 58 days it will total up to 1034.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2018 - - - 425
2019 790
85.9% QoQ
727
-8.0% QoQ
654
-10.0% QoQ
638
50.1% YoY -2.4% QoQ
2020 690
-12.7% YoY 8.2% QoQ
640
-12.0% YoY -7.2% QoQ
603
-7.8% YoY -5.8% QoQ
649
1.7% YoY 7.6% QoQ
2021 638
-7.5% YoY -1.7% QoQ
764
19.4% YoY 19.7% QoQ
680
12.8% YoY -11.0% QoQ
790
21.7% YoY 16.2% QoQ
2022 856
34.2% YoY 8.4% QoQ
703
-8.0% YoY -17.9% QoQ
669
-1.6% YoY -4.8% QoQ
796
0.8% YoY 19.0% QoQ
2023 667
-22.1% YoY -16.2% QoQ
778
10.7% YoY 16.6% QoQ
808
20.8% YoY 3.9% QoQ
382
-52.0% YoY -52.7% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and healthcare search interestLast update: November 08 2023 15:58:35.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 09 2023 02:39:52.

The average 5 years interest of healthcare was 54.97 per week.
The last year interest of healthcare compared to the last 5 years has changed by 6.64%.
The interest for healthcare is seasonal.
The last year interest is comparable to 5 years ago. It has changed only by 7.9%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 20:15:07.

After 39 days of this quarter the interest is at 342.0. Based on that we can calculate that during remaining 52 days it will total up to 798.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019558
717
28.5% QoQ
632
-11.9% QoQ
681
7.8% QoQ
2020 882
58.1% YoY 29.5% QoQ
723
0.8% YoY -18.0% QoQ
710
12.3% YoY -1.8% QoQ
584
-14.2% YoY -17.7% QoQ
2021 760
-13.8% YoY 30.1% QoQ
626
-13.4% YoY -17.6% QoQ
561
-21.0% YoY -10.4% QoQ
564
-3.4% YoY 0.5% QoQ
2022 814
7.1% YoY 44.3% QoQ
813
29.9% YoY -0.1% QoQ
677
20.7% YoY -16.7% QoQ
697
23.6% YoY 3.0% QoQ
2023 891
9.5% YoY 27.8% QoQ
744
-8.5% YoY -16.5% QoQ
644
-4.9% YoY -13.4% QoQ
752
7.9% YoY 16.8% QoQ
2024 342
-61.6% YoY -54.5% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and biotechnology search interestLast update: February 09 2024 20:15:07.
Correlation coefficient between keyword and revenue is -0.44
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 20:15:09.

The average 5 years interest of biotechnology was 55.07 per week.
The last year interest of biotechnology compared to the last 5 years has changed by 3.36%.
The interest for biotechnology is seasonal.
The last year interest is comparable to 5 years ago. It has changed only by 1.53%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for TRVN
Earnings date: 2024-03-06 After close
Company name: Trevena Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2025-12-22T05:00:00.000Z

US FDA
Approval of Olinvyk, Nda #210730 (Labeling)

2025-05-15T08:09:22-04:00

SEC
8-K Form - Current report, items 1.01, 1.02, 3.02, and 9.01 - TREVENA INC (0001429560) (Filer)

2025-04-08T09:20:54-04:00

SEC
25-NSE Form - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities - TREVENA INC (0001429560) (Subject)

2025-03-31T16:01:19-04:00

SEC
NT 10-K Form - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 - TREVENA INC (0001429560) (Filer)

2025-02-03T16:05:31-05:00

SEC
8-K Form - Current report, items 5.02 and 9.01 - TREVENA INC (0001429560) (Filer)

2024-11-14T16:43:11-05:00

SEC
SC 13G/A Form - [Amend] Statement of Beneficial Ownership by Certain Investors - TREVENA INC (0001429560) (Subject)

2024-11-14T18:51:49Z

Analyst Upgrades
HC Wainwright & Co. Downgrades Trevena to Neutral, Maintains $5 Price Target

2024-11-07T07:15:31-05:00

SEC
10-Q Form - Quarterly report [Sections 13 or 15(d)] - TREVENA INC (0001429560) (Filer)

2024-11-07T07:05:12-05:00

SEC
8-K Form - Current report, items 2.02, 5.02, and 9.01 - TREVENA INC (0001429560) (Filer)

2024-11-07T12:01:00Z

GlobeNewswire
Trevena Reports Third Quarter 2024 Results and Provides Business Update

2024-10-10T17:08:47-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - TREVENA INC (0001429560) (Issuer)

2024-10-10T17:07:55-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - TREVENA INC (0001429560) (Issuer)

2024-10-10T17:07:16-04:00

SEC
4 Form - Statement of changes in beneficial ownership of securities - TREVENA INC (0001429560) (Issuer)

2024-10-10T16:39:36-04:00

SEC
8-K Form - Current report, items 5.02 and 9.01 - TREVENA INC (0001429560) (Filer)

2024-10-04T16:10:20-04:00

SEC
8-K Form - Current report, items 3.01, 7.01, and 9.01 - TREVENA INC (0001429560) (Filer)